Sign In
Buy VBIV
$0.0653
+0 (+0%)
At Close: Nov 15, 2024
7 Penny Stocks Waiting on The FDA for Rocket Fuel
12:43pm, Thursday, 09'th Sep 2021
News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on Investor
Best Penny Stocks to Buy in September 2021? 3 to Watch Right Now
09:05am, Wednesday, 01'st Sep 2021
Which penny stocks are on your watchlist this month? The post Best Penny Stocks to Buy in September 2021?
VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates
10:42am, Monday, 02'nd Aug 2021
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 12.50% and -73.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
08:00am, Monday, 02'nd Aug 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today report
VBI Vaccines: Turning My Focus To VBI-1901
06:01am, Thursday, 15'th Jul 2021
My coverage of VBI Vaccines has been overly focused on the company's infectious disease programs and I have discounted the company's glioblastoma candidate, VBI-1901. The company presented impressive
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
04:05pm, Thursday, 01'st Jul 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today report
Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday
04:14pm, Tuesday, 29'th Jun 2021
Investors almost seemed ready to take profits once shares hit their highest level since February.
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial
09:16am, Tuesday, 29'th Jun 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine candidate VBI-2902a. VBI-2902a was
9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again
09:13am, Tuesday, 29'th Jun 2021
These penny stocks are showing high bullish sentiment right now; are they on your watchlist? The post 9 Hot Penny Stocks to Watch With AMC Stock on the Rise Again appeared first on Penny Stocks to Buy
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
07:35am, Tuesday, 29'th Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announc
VBI Vaccines (VBIV) is in Overbought Territory: What's Next?
09:01am, Friday, 11'th Jun 2021
VBI Vaccines (VBIV) has moved higher as of late, but there could definitely be trouble on the horizon for this company
VBI Vaccines Announces Results of Annual General Meeting
06:18pm, Wednesday, 09'th Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of di
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status
11:16am, Wednesday, 09'th Jun 2021
VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival Data
10:38am, Tuesday, 08'th Jun 2021
The FDA has granted Fast Track Designation for VBI Vaccines Inc's (NASDAQ: VBIV) VBI-1901, its cancer vaccine immunotherapeutic candidate to treat recurrent glioblastoma (GBM) patients with first
VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVentures
10:44am, Friday, 21'st May 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced an agreement to draw down a $12 million second tranche under its previously announced debt financing facility with K2 HealthVentures (K2HV). Under the
